Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Rigel Pharms
Fostamatinib disodium is an orally available prodrug of the SYK kinase inhibitor R406. It inhibits spleen tyrosine kinase, blocking Fc-gamma receptor and B-cell receptor signaling and reducing antibody-mediated destruction of platelets. It is studied in rheumatoid arthritis, idiopathic thrombocytopenic purpura and IgA nephropathy.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Nov 5, 2025). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT02077192 | Phase 3 | Immune Thrombocytopenic Purpura | Completed | RIGL |
| NCT02433236 | Phase 2 | IGA Nephropathy | Withdrawn | RIGL |
| NCT00665626 | Phase 2 | Rheumatoid Arthritis | Completed | RIGL |
| NCT00706342 | Phase 2 | Purpura, Thrombocytopenic, Idiopathic | Completed | RIGL |
| NCT03363334 | N/A | Immune Thrombocytopenic Purpura | No longer available | RIGL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
IGA NephropathyImmune Thrombocytopenic PurpuraPurpura, Thrombocytopenic, IdiopathicRheumatoid Arthritis
Updated Nov 1, 2026. Something wrong or missing? Report it on the RIGL page.
See RIGL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RIGL catalysts and pipeline →